Levemir Penfill

Insulin detemir, the active ingredient in Levemir Penfill, is a long‑acting insulin analog presented as a solution for injection (penfill) for subcutaneous use. It treats type 1 and type 2 diabetes mellitus in adults and children as indicated.

GNH USA supplies Levemir Penfill as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levemir Penfill is a basal insulin used to manage chronic hyperglycaemia in diabetes mellitus.

Type 1 diabetes mellitus: provides basal insulin coverage to maintain fasting glucose levels. Type 2 diabetes mellitus: adds basal insulin to oral agents for improved glycaemic control. Pediatric diabetes (age ≥ 2 years): supplies long‑acting insulin needed for basal therapy in children.

Levemir Penfill may cause adverse reactions ranging from mild to severe.

Common Side Effects: - Hypoglycaemia: low blood glucose episodes, especially if meals are missed. - Injection‑site reactions: redness, swelling, or itching at the injection site. - Weight gain: modest increase associated with insulin therapy. - Lipodystrophy: localized changes in subcutaneous fat. - Edema: mild fluid retention.

Serious or Rare Side Effects: - Severe hypoglycaemia: seizures or loss of consciousness. - Allergic reactions: rash, urticaria, or anaphylaxis. - Insulin antibodies: may alter insulin action. - Acute pancreatitis: rare but serious pancreatic inflammation. - Ketoacidosis: possible if insulin is abruptly discontinued.

Before using Levemir Penfill, consider the following safety measures.

Dose adjustment: individualise the dose based on glucose monitoring and clinical response. Renal impairment: monitor renal function and adjust dose as needed. Hepatic impairment: use with caution and observe for altered glucose control. Pregnancy: only use if the potential benefit justifies the potential risk to the fetus. Hypoglycaemia risk: educate patients on recognising and treating low blood glucose. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levemir Penfill can interact with other medicines, affecting blood glucose levels.

Major Interactions (Avoid): - Concurrent sulfonylureas: increased risk of severe hypoglycaemia. - Beta‑blockers: may mask hypoglycaemia symptoms, complicating detection.

Moderate Interactions (Monitor Closely): - ACE inhibitors: may potentiate insulin’s glucose‑lowering effect. - Thiazide diuretics: can raise blood glucose, requiring dose adjustment. - Oral contraceptives: may alter insulin requirements, necessitating closer monitoring.